Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUstodiol vs RInger: whaT Is the Best Agent?
2014-003818-92Phase 4Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Oct 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of HTK Custodiol in Thoracoabdominal aortic aneurysm (TAAA), aortic aneurysm and acute kidney failure (AKF) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Reduction in acute kidney injury. Started Oct 2014; status: completed.
02
Drugs
HTK Custodiol
03
Conditions
Thoracoabdominal aortic aneurysm (TAAA)aortic aneurysmacute kidney failure (AKF)
Beyond the preview
Go deeper on 2014-003818-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003818-92.